JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kunz, P.
Right arrow Articles by Kinscherf, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kunz, P.
Right arrow Articles by Kinscherf, R.

Angiopoietin-2 Overexpression in Morris Hepatoma Results in Increased Tumor Perfusion and Induction of Critical Angiogenesis-Promoting Genes

Pierre Kunz1–3,, Johannes Hoffend3, Annette Altmann2,3, Antonia Dimitrakopoulou-Strauss2, Dirk Koczan4, Michael Eisenhut5, Gabriel A. Bonaterra1, Thomas J. Dengler6, Walter Mier3, Uwe Haberkorn*,2,3 and Ralf Kinscherf*,1

1 Department of Anatomy and Cell Biology III, University of Heidelberg, Heidelberg, Germany; 2 Clinical Cooperation Unit Nuclear Medicine, DKFZ, Heidelberg, Germany; 3 Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany; 4 Department of Immunology, University of Rostock, Rostock, Germany; 5 Department of Radiopharmaceutical Chemistry, DKFZ, Heidelberg, Germany; and 6 Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany


Figure 1
View larger version (11K):

[in a new window]
 
FIGURE 1.  Proliferation of HUVECs with or without (w/o) bFGF (1 ng/mL) cocultured with WT-MH3924A or Ang-2-MH3924A. Stimulation with low concentration of bFGF is not sufficient to induce proliferation of HUVECs. Note that Ang-2-MH3924A only induces proliferation in HUVEC in presence of bFGF. Values are mean ± SEM (n = 3 in duplicate; P = 0.003, Ang-2-MH3924A with vs. without bFGF; P = 0.004 vs. WT-MH3924A with bFGF).

 

Figure 2
View larger version (10K):

[in a new window]
 
FIGURE 2.  Tumor growth in RNU rats after transplantation of WT-MH3924A or Ang-2-MH3924A until 38 d after inoculation. Values are mean ± SEM (n = 8 for each group).

 

Figure 3
View larger version (39K):

[in a new window]
 
FIGURE 3.  H215O PET images of rats with WT- (A) and angiopoietin-2–expressing hepatoma. T = tumor.

 

Figure 4
View larger version (12K):

[in a new window]
 
FIGURE 4.  H215O PET. Tumor tissue perfusion (K1, k2, DV, and VB values) measured in WT-MH3924A (n = 6) and Ang-2-MH3924A (n = 6) tumors of ACI rats. Ang-2–overexpressing tumors demonstrate increased K1 (A), which was not significant with P = 0.06, whereas k2 was not changed in Ang-2-MH3924A (B). Fractional volume of distribution (DV) significantly increased in Ang-2-MH3924A (C), whereas vascular fraction (VB) remained unchanged (D).

 

Figure 5
View larger version (13K):

[in a new window]
 
FIGURE 5.  Time–activity curves for WT- and angiopoietin-2–expressing hepatomas (A). Blood pool within tumors, measured after 68Ga-DOTA-albumin application (representing permeability of vessels for albumin) showed no difference (B).

 

Figure 6
View larger version (83K):

[in a new window]
 
FIGURE 6.  Micro- and macrovascularization of Morris hepatoma identified by CD31 or {alpha}-actin staining. Representative pictures are shown. Note that Ang-2-MH3924A tumors revealed significant increase in microvessel density (as indicated by CD31 staining) compared with WT-MH3924A tumors, both in center and periphery of tumors as well as in macrovascularization (as indicated by {alpha}-actin staining). (x100)

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.